Tectonic Therapeutic (TECX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
24 Apr, 2026Executive summary
Annual meeting scheduled for June 8, 2026, with voting open until June 7, 2026, at 11:59 PM ET.
Shareholders can access proxy materials online or request paper/email copies by May 25, 2026.
Meeting will be held virtually, allowing remote participation and voting.
Voting matters and shareholder proposals
Election of two directors: Timothy A. Springer, Ph.D., and Stefan Vitorovic, M.S., M.B.A.
Ratification of Deloitte & Touche LLP as independent auditor for fiscal year ending December 31, 2026.
Advisory vote on compensation of Named Executive Officers.
Provision for other business to be addressed as may properly come before the meeting.
Board of directors and corporate governance
Board recommends voting in favor of all proposals, including director nominees and auditor ratification.
Latest events from Tectonic Therapeutic
- Director elections, auditor ratification, and executive pay are key items at the 2026 virtual meeting.TECX
Proxy filing24 Apr 2026 - TX45 and TX2100 advance in the clinic, with differentiated strategies and strong preclinical data.TECX
Leerink Global Healthcare Conference 202611 Mar 2026 - Advancing novel therapies for pulmonary hypertension and HHT, with pivotal data expected by 2027.TECX
TD Cowen 46th Annual Health Care Conference4 Mar 2026 - Strong cash position and advancing clinical pipeline, with key trial results expected in 2026.TECX
Q4 202526 Feb 2026 - TX2100 targets HHT with a novel, selective anti-angiogenic approach and strong preclinical results.TECX
KOL event24 Feb 2026 - Reverse merger and clinical progress drive higher R&D spend, with cash runway into mid-2027.TECX
Q3 202413 Feb 2026 - TX-45 targets Group 2 PH with potential for monthly dosing and key data expected mid-2025.TECX
2024 Wells Fargo Healthcare Conference22 Jan 2026 - Anticipated 2025 data could transform Group 2 PH treatment in a multi-billion dollar market.TECX
Piper Sandler 36th Annual Healthcare Conference12 Jan 2026 - TX45, a long-acting relaxin, targets hemodynamic and functional gains in PH-HFpEF.TECX
Status Update11 Jan 2026